Past Press Releases - Noxxon Pharma AG

July 31, 2014
NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94)
NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia More

June 2, 2014
NOXXON’s Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA
Full clinical data presentation for anti-CCL2 /MCP-1 Spiegelmer® emapticap pegol (NOX-E36). More

December 4, 2012
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94
Anemia of Chronic Disease Study is Fourth Phase II Initiated by NOXXON in 2012. More

June 19, 2012
NOXXON Initiates Phase IIa of anti-CCL2/MCP-1 Spiegelmer NOX-E36
NOXXON Initiates Phase IIa of anti-CCL2/MCP-1 Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy More

February 3, 2011
Noxxon expands management team
Noxxon Pharma AG (website), announced today the appointment of Dr Matthias Baumann as Chief Medical Officer and member of the management board of the company. More

June 28, 2010
NOXXON Pharma AG announces management changes
NOXXON Pharma AG, Berlin, Germany announced today that CEO Dr Frank Morich will leave the company effective August 15, 2010 to take up the position Executive Vice President, International Operations, at Takeda Pharmaceutical Company Limited. More

May 27, 2010
NOXXON Pharma AG raises €33 million in Series D round
NOXXON Pharma AG (NOXXON), a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers, announced today the successful closing of a €33 million Series D round of financing. More

May 3, 2010
NOXXON announces the completion of the first-in-human clinical trial with Spiegelmer NOX-A12
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer NOX-A12. More

October 12, 2009
NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer NOX-E36
Good safety and pharmacodynamic profile and additional good subcutaneous bioavailability. More

June 8, 2009
NOXXON announces initiation of first clinical trial with a Spiegelmer
NOXXON announced today the successful initial dosing of healthy volunteers with Spiegelmer NOX-E36 in the company's first-in-human clinical trial. More

July 8, 2008
NOXXON Pharma announces appointment of Lawrence E. Posner to its board of directors
Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers, announced today the appointment of Lawrence E. Posner, MD, to its Board of Directors. More

April 7, 2008
NOXXON receives research grant from the Federal Ministry of Education and Research
NOXXON announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF). More

November 9, 2007
NOXXON Pharma AG announces research & development alliance with Roche regarding inflammatory disease
NOXXON Pharma AG (NOXXON) announced today that it has entered into a research and development collaboration with Roche regarding the discovery and development of Spiegelmers for the treatment of inflammatory diseases. More